X‑Chem Acquires Glamorous AI — Immediately Creating a Leader in DEL-Powered AI Solutions

October 28, 2021

Combination Accelerates Outcomes in Early Drug Discovery WALTHAM, Mass.; Oct. 28, 2021 – X-Chem, the pioneer of DNA-encoded library (DEL)...


X‑Chem Acquires ComInnex

October 25, 2021

Extending Functional and Global Leadership in Small Molecule Drug Discovery WALTHAM, Mass.; Oct. 25, 2021 – X-Chem, the pioneer of...


LEO Pharma and X‑Chem Enter Into Discovery Research Agreement

July 6, 2021

Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications BALLERUP, Denmark, and WALTHAM, Mass., US;...


X‑Chem Announces OpenDEX DNA-Encoded Library Screening

May 11, 2021

Flexible and Cost-Effective Solution for Screening Billions of Small Molecules WALTHAM, Mass.; May 11, 2021 (Business Wire) – X-Chem, the...


X‑Chem Enters into Multitarget Oncology Discovery Research Collaboration and License Agreement with Genentech

February 2, 2021

 Collaboration Includes Licensing of Preclinical Small Molecule Program  WALTHAM, Mass.; Feb. 2, 2021 (Business Wire) – X-Chem, Inc., a global...


X‑Chem acquires IntelliSyn and sister company, AviSyn, to extend and streamline drug discovery service range

January 26, 2021

Acquisition allows X-Chem to offer a more comprehensive, integrated, screen-to-lead drug discovery process to pharma and biotech clients IntelliSyn’s Founder...


Servier and X‑Chem Announce Drug Discovery Collaboration in Neurological Diseases

January 6, 2021

Paris and Waltham, Mass.; Jan. 6, 2021 (Business Wire) – Servier, a global pharmaceutical Group and X-Chem, Inc., a privately...


X‑Chem Announces Licensing of Second Drug Discovery Program to Otsuka

January 4, 2021

Waltham, Mass – January 4, 2020 – X-Chem Inc. (X-Chem), the global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced today that Otsuka Pharmaceutical Co., Ltd.…